FDA Bars Ranbaxy Drugs For Manufacturing Violations

Law360, New York (September 17, 2008, 12:00 AM EDT) -- The U.S. Food and Drug Administration said it has barred more than 30 drugs manufactured by Ranbaxy Laboratories Ltd. from entering the U.S. after the company failed to address serious manufacturing deficiencies at two of its plants in India.

The agency announced Tuesday it has issued an import alert for drugs manufactured at the two plants, including generic versions of the allergy treatment Claritin, cholesterol-lowering drug Zocor, and heartburn treatment Zantac.

Officials are not requiring the drugs to be pulled off the market, saying they haven't...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.